POSITIVE STELLUNGNAHME DES CHMP UNTERSTÜTZT BREITERE ANWENDUNG VON AMGENS REPATHA® VOR ERSTEM HERZINFARKT ODER SCHLAGANFALL

RegulatoryRepathaPositive

AI Analysis

Summary

The CHMP issued a positive opinion supporting the broader use of Amgen's Repatha for primary prevention of myocardial infarction and stroke based on Phase 3 clinical trial data demonstrating significant risk reduction.

Clinical Trial Data

Phase

Phase 3

Primary Endpoint

Met

Outcome Details

CHMP positive opinion supporting broader use of Repatha for primary cardiovascular prevention

Importance:7/10

Sentiment:

0.85

CHMP opinionPCSK9 inhibitorcardiovascularprimary preventionregulatory approval

Related Companies

$AMGN

Read the original article

Published by PR Newswire Biotech on July 30, 2026 5:07 PM

Read Original